1
|
Hryckowian ND, Ramírez-Flores CJ, Zinda C, Park SC, Kelty MT, Knoll LJ. Host cell-specific metabolism of linoleic acid controls Toxoplasma gondii growth in cell culture. Infect Immun 2024:e0029924. [PMID: 39194219 DOI: 10.1128/iai.00299-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Accepted: 07/19/2024] [Indexed: 08/29/2024] Open
Abstract
The obligate intracellular parasite Toxoplasma gondii can infect and replicate in any warm-blooded cell tested to date, but much of our knowledge about T. gondii cell biology comes from just one host cell type: human foreskin fibroblasts (HFFs). To expand our knowledge of host-parasite lipid interactions, we studied T. gondii in intestinal epithelial cells, the first site of host-parasite contact following oral infection and the exclusive site of parasite sexual development in feline hosts. We found that highly metabolic Caco-2 cells are permissive to T. gondii growth even when treated with high levels of linoleic acid (LA), a polyunsaturated fatty acid (PUFA) that kills parasites in HFFs. Caco-2 cells appear to sequester LA away from the parasite, preventing membrane disruptions and lipotoxicity that characterize LA-induced parasite death in HFFs. Our work is an important step toward understanding host-parasite interactions in feline intestinal epithelial cells, an understudied but important cell type in the T. gondii life cycle.
Collapse
Affiliation(s)
- Nicole D Hryckowian
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Carlos J Ramírez-Flores
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Caitlin Zinda
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Sung Chul Park
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Martin T Kelty
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Laura J Knoll
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
2
|
Babkov D, Eliseeva N, Adzhienko K, Bagmetova V, Danilov D, McReynolds CB, Morisseau C, Hammock BD, Burmistrov V. Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain. Int J Mol Sci 2024; 25:8841. [PMID: 39201526 PMCID: PMC11354909 DOI: 10.3390/ijms25168841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Revised: 08/02/2024] [Accepted: 08/12/2024] [Indexed: 09/02/2024] Open
Abstract
Inhibition of soluble epoxide hydrolase (sEH) is a promising therapeutic strategy for treating neuropathic pain. These inhibitors effectively reduce diabetic neuropathic pain and inflammation induced by Freund's adjuvant which makes them a suitable alternative to traditional opioids. This study showcased the notable analgesic effects of compound AMHDU (1,1'-(hexane-1,6-diyl)bis(3-((adamantan-1-yl)methyl)urea)) in both inflammatory and diabetic neuropathy models. While lacking anti-inflammatory properties in a paw edema model, AMHDU is comparable to celecoxib as an analgesic in 30 mg/kg dose administrated by intraperitoneal injection. In a diabetic tactile allodynia model, AMHDU showed a prominent analgesic activity in 10 mg/kg intraperitoneal dose (p < 0.05). The effect is comparable to that of gabapentin, but without the risk of dependence due to a different mechanism of action. Low acute oral toxicity (>2000 mg/kg) and a high therapeutic index makes AMHDU a promising candidate for further structure optimization and preclinical evaluation.
Collapse
Affiliation(s)
- Denis Babkov
- Department of Pharmacology & Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd 400131, Russia; (D.B.); (V.B.)
| | - Natalya Eliseeva
- Department of Pharmacology & Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd 400131, Russia; (D.B.); (V.B.)
| | - Kristina Adzhienko
- Department of Pharmacology & Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd 400131, Russia; (D.B.); (V.B.)
| | - Viktoria Bagmetova
- Department of Pharmacology & Bioinformatics, Scientific Center for Innovative Drugs, Volgograd State Medical University, Volgograd 400131, Russia; (D.B.); (V.B.)
| | - Dmitry Danilov
- Department of Organic Chemistry, Volgograd State Technical University, Volgograd 400005, Russia;
| | - Cynthia B. McReynolds
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA (C.M.)
| | - Christophe Morisseau
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA (C.M.)
| | - Bruce D. Hammock
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA (C.M.)
| | - Vladimir Burmistrov
- Department of Organic Chemistry, Volgograd State Technical University, Volgograd 400005, Russia;
| |
Collapse
|
3
|
Hryckowian ND, Zinda C, Park SC, Kelty MT, Knoll LJ. Host cell-specific metabolism of linoleic acid controls Toxoplasma gondii growth in cell culture. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2024:2024.03.22.586332. [PMID: 38562845 PMCID: PMC10983968 DOI: 10.1101/2024.03.22.586332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
The obligate intracellular parasite Toxoplasma gondii can infect and replicate in any warm-blooded cell tested to date, but much of our knowledge about T. gondii cell biology comes from just one host cell type: human foreskin fibroblasts (HFFs). To expand our knowledge of host-parasite lipid interactions, we studied T. gondii in intestinal epithelial cells, the first site of host-parasite contact following oral infection and the exclusive site of parasite sexual development in feline hosts. We found that highly metabolic Caco-2 cells are permissive to T. gondii growth even when treated with high levels of linoleic acid (LA), a polyunsaturated fatty acid (PUFA) that kills parasites in HFFs. Caco-2 cells appear to sequester LA away from the parasite, preventing membrane disruptions and lipotoxicity that characterize LA-induced parasite death in HFFs. Our work is an important step toward understanding host-parasite interactions in feline intestinal epithelial cells, an understudied but important cell type in the T. gondii life cycle.
Collapse
Affiliation(s)
- Nicole D. Hryckowian
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI, USA
| | - Caitlin Zinda
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI, USA
| | - Sung Chul Park
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI, USA
| | - Martin T. Kelty
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI, USA
| | - Laura J. Knoll
- Department of Medical Microbiology & Immunology, University of Wisconsin-Madison, Madison, WI, USA
| |
Collapse
|
4
|
Carlson A, Johnson PJ, Lei Z, Keegan KG. Anti-nociceptive efficacy of the soluble epoxide hydrolase inhibitor t-TUCB in horses with mechanically induced lameness. Res Vet Sci 2022; 152:504-509. [PMID: 36174370 DOI: 10.1016/j.rvsc.2022.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Revised: 08/30/2022] [Accepted: 09/12/2022] [Indexed: 10/14/2022]
Abstract
INTRODUCTION Soluble epoxide hydrolase (sEH) inhibitors are novel anti-inflammatory and analgesic agents that could improve pain management in horses. The objective of the present study was to evaluate the anti-nociceptive effect of a single-dose intravenous administration of the sEH inhibitor trans-4-{4-[3-(4-trifluro-methoxy-phenyl)-ureido]-cyclohexyloxy}-benzoic acid (t-TUCB) using an adjustable heart bar shoe (a-HBS) model of lameness. We hypothesized that t-TUCB would improve objective and subjective lameness measures compared to the control. MATERIALS AND METHODS Reversible lameness was induced in 8 horses for 24 h using an a-HBS in a randomized, crossover design. A vehicle-control placebo (DMSO) or t-TUCB (1 mg/kg) was intravenously administered at time 0 following a baseline induced lameness evaluation. Blood was collected and lameness was objectively measured with an inertial sensor system at 0-, 1-, 3-, 6-, 12-, and 24-h time points. Front-facing videos were obtained at each time point for subjective evaluation by three blinded evaluators using a visual analog scale (VAS). RESULTS Treatment with t-TUCB significantly decreased (i.e. improved) lameness compared to placebo at 1-h and compared to baseline at 1-, 3-, and 6-h following administration. Lameness significantly increased (i.e. worsened) from baseline in placebo-treated horses 12 h after administration. All horses returned to baseline soundness within 24 h of reversing lameness. CONCLUSION Treatment with single-dose IV administration of t-TUCB improved lameness induced by the a-HSB, suggesting that t-TUCB has anti-nociceptive effects in horses. CLINICAL RELEVANCE The soluble epoxide hydrolase inhibitor, t-TUCB, is a promising novel analgesic for horses.
Collapse
Affiliation(s)
- Alexandra Carlson
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.
| | - Philip J Johnson
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.
| | - Zhentian Lei
- Department of Biochemistry, MU Metabolomics Center, University of Missouri, Columbia, MO, USA.
| | - Kevin G Keegan
- Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.
| |
Collapse
|
5
|
Effects of cyclooxygenase and soluble epoxide hydrolase inhibitors on apoptosis of cultured primary equine chondrocytes. Res Vet Sci 2022; 147:44-49. [DOI: 10.1016/j.rvsc.2022.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 02/24/2022] [Accepted: 04/08/2022] [Indexed: 11/19/2022]
|
6
|
Wagner KM, Yang J, Morisseau C, Hammock BD. Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation. Front Pharmacol 2022; 12:778470. [PMID: 34975481 PMCID: PMC8719166 DOI: 10.3389/fphar.2021.778470] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2021] [Accepted: 11/08/2021] [Indexed: 01/28/2023] Open
Abstract
The soluble epoxide hydrolase (sEH) enzyme is a major regulator of bioactive lipids. The enzyme is highly expressed in liver and kidney and modulates levels of endogenous epoxy-fatty acids, which have pleiotropic biological effects including limiting inflammation, neuroinflammation, and hypertension. It has been hypothesized that inhibiting sEH has beneficial effects on limiting obesity and metabolic disease as well. There is a body of literature published on these effects, but typically only male subjects have been included. Here, we investigate the role of sEH in both male and female mice and use a global sEH knockout mouse model to compare the effects of diet and diet-induced obesity. The results demonstrate that sEH activity in the liver is modulated by high-fat diets more in male than in female mice. In addition, we characterized the sEH activity in high fat content tissues and demonstrated the influence of diet on levels of bioactive epoxy-fatty acids. The sEH KO animals had generally increased epoxy-fatty acids compared to wild-type mice but gained less body weight on higher-fat diets. Generally, proinflammatory prostaglandins and triglycerides were also lower in livers of sEH KO mice fed HFD. Thus, sEH activity, prostaglandins, and triglycerides increase in male mice on high-fat diet but are all limited by sEH ablation. Additionally, these changes also occur in female mice though at a different magnitude and are also improved by knockout of the sEH enzyme.
Collapse
Affiliation(s)
- Karen M Wagner
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, United States
| | - Jun Yang
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, United States
| | - Christophe Morisseau
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, United States
| | - Bruce D Hammock
- Department of Entomology and Nematology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, United States
| |
Collapse
|
7
|
McReynolds CB, Yang J, Guedes A, Morisseau C, Garcia R, Knych H, Tearney C, Hamamoto B, Hwang SH, Wagner K, Hammock BD. Species Differences in Metabolism of Soluble Epoxide Hydrolase Inhibitor, EC1728, Highlight the Importance of Clinically Relevant Screening Mechanisms in Drug Development. Molecules 2021; 26:5034. [PMID: 34443621 PMCID: PMC8399023 DOI: 10.3390/molecules26165034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 08/13/2021] [Accepted: 08/14/2021] [Indexed: 11/21/2022] Open
Abstract
There are few novel therapeutic options available for companion animals, and medications rely heavily on repurposed drugs developed for other species. Considering the diversity of species and breeds in companion animal medicine, comprehensive PK exposures in the companion animal patient is often lacking. The purpose of this paper was to assess the pharmacokinetics after oral and intravenous dosing in domesticated animal species (dogs, cats, and horses) of a novel soluble epoxide hydrolase inhibitor, EC1728, being developed for the treatment of pain in animals. Results: Intravenous and oral administration revealed that bioavailability was similar for dogs, and horses (42 and 50% F) but lower in mice and cats (34 and 8%, respectively). Additionally, clearance was similar between cats and mice, but >2× faster in cats vs. dogs and horses. Efficacy with EC1728 has been demonstrated in mice, dogs, and horses, and despite the rapid clearance of EC1728 in cats, analgesic efficacy was demonstrated in an acute pain model after intravenous but not oral dosing. Conclusion: These results demonstrate that exposures across species can vary, and investigation of therapeutic exposures in target species is needed to provide adequate care that addresses efficacy and avoids toxicity.
Collapse
Affiliation(s)
- Cindy B. McReynolds
- UC Davis Comprehensive Cancer Center, Department of Entomology and Nematology, University of California, Davis, Davis, CA 95616, USA; (C.B.M.); (J.Y.); (C.M.); (S.H.H.); (K.W.)
- EicOsis, 1930 5th Street, Suite A, Davis, CA 95616, USA
| | - Jun Yang
- UC Davis Comprehensive Cancer Center, Department of Entomology and Nematology, University of California, Davis, Davis, CA 95616, USA; (C.B.M.); (J.Y.); (C.M.); (S.H.H.); (K.W.)
- EicOsis, 1930 5th Street, Suite A, Davis, CA 95616, USA
| | - Alonso Guedes
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA; (A.G.); (C.T.)
| | - Christophe Morisseau
- UC Davis Comprehensive Cancer Center, Department of Entomology and Nematology, University of California, Davis, Davis, CA 95616, USA; (C.B.M.); (J.Y.); (C.M.); (S.H.H.); (K.W.)
| | - Roberto Garcia
- Dechra Development LLC, 1 Monument Sq, Portland, ME 04101, USA;
| | - Heather Knych
- K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA; (H.K.); (B.H.)
- Department of Veterinary Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA
| | - Caitlin Tearney
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108, USA; (A.G.); (C.T.)
| | - Briana Hamamoto
- K.L. Maddy Equine Analytical Pharmacology Laboratory, School of Veterinary Medicine, University of California, Davis, Davis, CA 95616, USA; (H.K.); (B.H.)
| | - Sung Hee Hwang
- UC Davis Comprehensive Cancer Center, Department of Entomology and Nematology, University of California, Davis, Davis, CA 95616, USA; (C.B.M.); (J.Y.); (C.M.); (S.H.H.); (K.W.)
- EicOsis, 1930 5th Street, Suite A, Davis, CA 95616, USA
| | - Karen Wagner
- UC Davis Comprehensive Cancer Center, Department of Entomology and Nematology, University of California, Davis, Davis, CA 95616, USA; (C.B.M.); (J.Y.); (C.M.); (S.H.H.); (K.W.)
- EicOsis, 1930 5th Street, Suite A, Davis, CA 95616, USA
| | - Bruce D. Hammock
- UC Davis Comprehensive Cancer Center, Department of Entomology and Nematology, University of California, Davis, Davis, CA 95616, USA; (C.B.M.); (J.Y.); (C.M.); (S.H.H.); (K.W.)
- EicOsis, 1930 5th Street, Suite A, Davis, CA 95616, USA
| |
Collapse
|